Androgen Deprivation Therapy (ADT) Market: Industry Outlook, Regional Analysis, And Key Players 2026

Androgen deprivation therapy:

Androgen deprivation therapy (ADT) is a hormone therapy for prostate cancer in men that works by removing excess androgen from the body. In testosterone and dihydrotestosterone, androgen is a sex hormone generated in the testes and adrenal gland. Androgen deprivation therapy involves removing androgen from the body to reduce adverse effects such as increasing cancer cell proliferation in the early stages and modulating androgen functions. To treat intermediate and high-risk prostate cancer, androgen deprivation therapy is combined with external beam radiotherapy.

Market Analysis:

The global Androgen Deprivation Therapy (ADT) Market is expected to grow at a CAGR of 5.0 per cent from USD 5647 million in 2019 to USD 7971.1 million by 2026, up from USD 5647 million in 2019. The global androgen deprivation therapy market is being propelled forward by rising prostate cancer cases and fatalities, breakthrough technologies, expanding healthcare expenditure and facilities, and increased global awareness and need for improved treatment. R&D organizations are working hard to create new androgen deprivation therapies for cancer. The introduction of new medications has significantly boosted the market for androgen deprivation therapy. However, market growth is limited by treatment resistance and side effects such as hot flashes, erectile dysfunction, low bone density, insulin resistance, etc.

The global Androgen Deprivation Therapy (ADT) Market is expected to grow in value as the number of cases of prostate cancer rises, as well as advances in healthcare and research. The Coronavirus pandemic has also shaped the global androgen deprivation therapy market.

Regional Analysis:

With a high frequency of prostate cancer, significant R&D investments, advanced healthcare expenditure, and the development of innovative immunotherapies, North America dominates the global Androgen Deprivation Therapy (ADT) Market. With its excellent healthcare facilities and substantial research spending, Europe owns the second-largest worldwide Androgen Deprivation Therapy (ADT) Market. The Asia-Pacific androgen deprivation therapy market is the fastest-growing, owing to the rising prevalence of prostate cancer, more awareness and government support, and improved healthcare facilities and research. With the increasing frequency of prostate cancer and the advancement of research and healthcare facilities in Latin America, the market for androgen deprivation therapy is growing.

Key Players:

Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Novartis International AG, Veru Inc., Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Orion Corporation, and AstraZeneca Plc. are the major key players of the Androgen Deprivation Therapy (ADT) Market.